for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Co-Diagnostics Inc

CODX.O

Latest Trade

28.38USD

Change

--(--)

Today's Range

--

 - 

--

52 Week Range

0.85

 - 

30.99

As of on the NASDAQ ∙ Minimum 15 minute delay

Latest Developments

Co-Diagnostics's Technology To Be Used In FDA-Authorized Self-Collected Covid-19 Saliva Test

Aug 3 (Reuters) - Co-Diagnostics Inc <CODX.O>::CO-DIAGNOSTICS, INC. TECHNOLOGY TO BE USED IN FDA-AUTHORIZED SELF-COLLECTED COVID-19 SALIVA TEST.CO-DIAGNOSTICS - CO'S PARTNER CLINICAL REFERENCE LABORATORY HAS RECEIVED FDA EUA FOR CRL RAPID RESPONSE A SALIVA-BASED COVID-19 TEST.

Co-Diagnostics Reports Q1 Revenue Of $1.5 Million

May 14 (Reuters) - Co-Diagnostics Inc <CODX.O>::CO-DIAGNOSTICS, INC. ANNOUNCES Q1 2020 RESULTS AND PROVIDES MID-SECOND QUARTER UPDATE.Q1 REVENUE $1.5 MILLION.Q1 REVENUE ESTIMATE $616,000 -- REFINITIV IBES DATA.QTRLY LOSS PER SHARE $0.05.

Ambalal Sarabhai Enterprises Says Unit's JV Granted Manufacturing License For Covid‐ 19 Rt‐Pcr Test Kits

April 27 (Reuters) - Ambalal Sarabhai Enterprises Ltd <AMBL.BO>::AMBALAL SARABHAI ENTERPRISES LTD SAYS COSARA DIAGNOSTICS PRIVATE LIMITED GRANTED MANUFACTURING LICENSE BY CDSO FOR COVID‐ 19 RT‐PCR TEST KITS..AMBALAL SARABHAI ENTERPRISES LTD SAYS COMPANY HAS STARTED TO MANUFACTURE TEST KITS BASED UPON LICENSE GRANTED AT ITS GUJARAT BASED PLANT..

Co-Diagnostics, Inc. COVID-19 Test Technology Validated For Use On Saliva Samples

April 16 (Reuters) - Co-Diagnostics Inc <CODX.O>::CO-DIAGNOSTICS, INC. COVID-19 TEST TECHNOLOGY VALIDATED FOR USE ON SALIVA SAMPLES.CO-DIAGNOSTICS - ORALDNA LABS RECENTLY VALIDATED COVID-19 PCR TEST BASED ON CO'S PATENTED COPRIMER TECHNOLOGY FOR USE WITH SALINE ORAL RINSE SAMPLES.CO-DIAGNOSTICS - ORALDNA LABS HAS NOTIFIED FDA OF INTENT TO USE VALIDATED TEST IN THEIR CAP ACCREDITED HIGH-COMPLEXITY LABORATOR.

Co-Diagnostics Completes Successful Clinical Evaluation Required For FDA Emergency Use Authorization

March 20 (Reuters) - Co-Diagnostics Inc <CODX.O>::CO-DIAGNOSTICS, INC COMPLETES SUCCESSFUL CLINICAL EVALUATION REQUIRED FOR FDA EMERGENCY USE AUTHORIZATION.CO-DIAGNOSTICS INC - COMPANY ACCELERATES U.S. SALES OF COVID-19 TEST PURSUANT TO NEW FDA POLICY.CO-DIAGNOSTICS INC - COMPANY'S APPLICATION FOR EUA IS CURRENTLY UNDER REVIEW BY FDA..

Co-Diagnostics - FDA Policy Change To Allow Rapid Domestic Expansion Of Co-Diagnostics Covid-19 Test

March 17 (Reuters) - Co-Diagnostics Inc <CODX.O>::FDA POLICY CHANGE TO ALLOW RAPID DOMESTIC EXPANSION OF CO-DIAGNOSTICS COVID-19 TEST.CO-DIAGNOSTICS INC - NEW FDA POLICY AIMED AT EXPEDITING AVAILABILITY OF COVID-19 DIAGNOSTICS WILL ALLOW CO TO EXPAND ITS PRESENCE IN U.S. MARKET.CO-DIAGNOSTICS INC - INTERNATIONAL SHIPMENTS OF COVID-19 TEST HAVE CONTINUED TO ESCALATE..CO-DIAGNOSTICS INC - "CONFIDENT IN OUR ABILITY TO MEET GROWING DEMAND FOR THIS DIAGNOSTIC".

Precheck Health Services Enters Into Distribution Agreement With Co-Diagnostics

March 11 (Reuters) - Precheck Health Services <HLTY.PK>::PRECHECK HEALTH SERVICES - ON MARCH 9, 2020, ENTERED INTO DISTRIBUTION AGREEMENT WITH CO-DIAGNOSTICS INC - SEC FILING.PRECHECK HEALTH SERVICES - UNDER AGREEMENT, CO-DIAGNOSTICS GRANTED CO EXCLUSIVE DISTRIBUTION RIGHTS TO ITS QPCR INFECTIOUS DISEASE KITS FOR RUSSIA.PRECHECK HEALTH SERVICES - DISTRIBUTION AGREEMENT HAS TERM OF ONE YEAR, BUT CAN BE TERMINATED BY EITHER PARTY AT ANY ON 30 DAYS' NOTICE.PRECHECK HEALTH - UNDER AGREEMENT CO-DIAGNOSTICS ALSO GRANTED CO EXCLUSIVE DISTRIBUTION RIGHTS TO LOGIX SMART COVID-19 PCR DIAGNOSTIC TEST FOR RUSSIA.PRECHECK HEALTH SERVICES - UNDER AGREEMENT, CO-DIAGNOSTICS ALSO GRANTED CO EXCLUSIVE DISTRIBUTION RIGHTS TO ITS CO-DX BOX(TM) INSTRUMENT FOR RUSSIA.

Co-Diagnostics Announces $4.2 Million Registered Direct Offering Priced At-The-Market

Feb 27 (Reuters) - Co-Diagnostics Inc <CODX.O>::CO-DIAGNOSTICS ANNOUNCES $4.2 MILLION REGISTERED DIRECT OFFERING PRICED AT-THE-MARKET.CO-DIAGNOSTICS - PURCHASE OF 470,000 SHARES AT PRICE OF $9.00 PER SHARE, IN REGISTERED DIRECT OFFERING PRICED AT-THE-MARKED.CO-DIAGNOSTICS INC - INTENDS TO USE NET PROCEEDS FROM OFFERING FOR ACQUISITION OF PCR (POLYMERASE CHAIN REACTION) EQUIPMENT.CO-DIAGNOSTICS - TO USE PROCEEDS FROM OFFERING TO BUY RAW MATERIALS TO USE IN SALE OF TESTS FOR INFECTIOUS DISEASE, INCLUDING CORONAVIRUS.

Co-Diagnostics Announces $5.0 Mln Registered Direct Offering Priced At-The-Market

Jan 24 (Reuters) - Co-Diagnostics Inc <CODX.O>::CO-DIAGNOSTICS ANNOUNCES $5.0 MILLION REGISTERED DIRECT OFFERING PRICED AT-THE-MARKET.CO-DIAGNOSTICS - ENTERED INTO DEFINITIVE AGREEMENTS WITH INSTITUTIONAL INVESTORS FOR PURCHASE OF 3.5 MILLION SHARES OF ITS COMMON STOCK, AT $1.45/SHARE.CO-DIAGNOSTICS - TO USE PROCEEDS FROM OFFERING FOR COMMERCIALIZATION & EXPANSION OF INFECTIOUS DISEASE TESTING, AMONG OTHER THINGS.

Co-Diagnostics Designs Test For New Coronavirus Using Coprimer Platform

Jan 23 (Reuters) - Co-Diagnostics Inc <CODX.O>::CO-DIAGNOSTICS, INC. DESIGNS TEST FOR NEW CORONAVIRUS USING COPRIMER PLATFORM.CO-DIAGNOSTICS - COMPLETED PRINCIPLE DESIGN WORK FOR PCR SCREENING TEST FOR NEW CORONAVIRUS, 2019-NCOV, INTENDED TO ADDRESS DETECTION OF VIRUS.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up